NEW YORK, May 4, 2018 /PRNewswire/ -- If you want a free Stock Review on ADMP, ALKS, PETS, and VRX sign up now at www.wallstequities.com/registration.On Thursday, May 03, 2018, US markets saw seven out of nine sectors finishing the day in red, one in green, and one in neutral territory. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite
On Thursday, shares in San Diego, California headquartered Adamis Pharmaceuticals Corp. recorded a trading volume of 188,406 shares. The stock ended the session 3.85% lower at $3.75. The Company's shares have gained 10.29% in the last month. The stock is trading above its 50-day moving average by 5.65%. Moreover, shares of Adamis Pharma, which develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the US, have a Relative Strength Index (RSI) of 53.37. Get the full research report on ADMP for free by clicking below at:
Dublin, Ireland headquartered Alkermes PLC's stock closed the day 1.52% lower at $43.31 with a total trading volume of 493,054 shares. The stock is trading below its 50-day moving average by 17.51%. Additionally, shares of Alkermes, which researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the US, Ireland, and internationally, have an RSI of 36.03. Free research on ALKS can be accessed at:
Shares in Delray Beach, Florida headquartered PetMed Express Inc. recorded a trading volume of 718,047 shares, which was above their three months average volume of 523.71 thousand shares. The stock ended yesterday's trading session 0.06% lower at $33.98. The Company's shares have advanced 43.07% in the past twelve months. The stock is trading below its 50-day moving average by 18.42%. Furthermore, shares of PetMed Express, which operates as a pet pharmacy in the US, have an RSI of 28.59. Sign up today for the free research report on PETS at:
Valeant Pharmaceuticals International
Laval, Canada headquartered Valeant Pharmaceuticals International Inc.'s stock finished Thursday's session 1.39% lower at $17.76 with a total trading volume of 6.53 million shares. The Company's shares have advanced 12.48% in the last month and 81.22% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 7.05% and 7.42%, respectively. Additionally, shares of Valeant Pharma, which operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter products, and medical devices, have an RSI of 62.01.
On April 06th, 2018, research firm Mizuho upgraded the Company's stock rating from 'Underperform' to 'Neutral' while revising its previous target price from $10 a share to $15 a share. Wall St. Equities' research coverage also includes the downloadable free report on VRX at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-drug-delivery-equities----adamis-pharma-alkermes-petmed-express-and-valeant-pharma-300642769.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All